Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Rademikibart
Rademikibart in prefilled syringe · 3 trials · 3 indications
Treatment failure is defined as death due to any cause, (re)admission to a hospital for COPD, ED (re)visit or unscheduled medical visit for worsening of COPD symptoms, or the necessity to intensify pharmacologic treatment (including second course of systemic steroids for COPD exacerbation) within 28 days after randomization.
Treatment failure is defined as death due to any cause, (re)admission to a hospital for asthma, ED (re)visit or unscheduled medical visit for worsening of asthma symptoms, or the necessity to intensify pharmacologic treatment (including second course of systemic steroids for asthma exacerbation) within 28 days after randomization.
| Arm | Type | Description |
|---|---|---|
| Rademikibart | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Rademikibart | DRUG | Single 300 mg dose as a 2-minute IV push |
| Rademikibart in prefilled syringe | COMBINATION_PRODUCT | Participants receive 600 mg (4mL) of rademikibart administered subcutaneously. |
| Matching placebo in prefilled syringe | DRUG | Participants receive 4mL of placebo matched to rademikibart administered subcutaneously. |
Inclusion Criteria - Asthma cohort * Body weight of ≥40 kg and BMI ≤45 kg/m2 at SV1a. * Physician-diagnosed asthma * Currently receiving treatment with low, medium, to high dose ICS in combination with at least 1 additional asthma controller medication. * Must have experienced at least 1 asthma exa...
Rademikibart in prefilled syringe is an investigational small molecule being developed for acute exacerbations of asthma and COPD. It is being studied as an add-on treatment in Phase 2 clinical trials for these respiratory conditions.
Rademikibart in prefilled syringe is being developed by Connect Biopharma Holdings Limited, a biopharmaceutical company traded on the NASDAQ under the ticker symbol CNTB.
Rademikibart in prefilled syringe is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 2 trials are active but not recruiting, and one is not yet recruiting.
Rademikibart in prefilled syringe is being studied in three Phase 2 trials: NCT06940141 for acute asthma exacerbation, NCT06940154 for acute COPD exacerbation, and NCT07705737 for acute asthma and COPD exacerbation. The trials are randomized, double-blind, and placebo-controlled.
Yes, Rademikibart in prefilled syringe is the same drug as Rademikibart. The prefilled syringe formulation is one delivery method being studied, while other trials use intravenous administration.